Objective：To evaluate the effect of Xuezhikang Capsule（血脂康胶囊） on the serum levels of inflammatory factors such as tumor necrosis factor-α（TNF-α） and interleukin-6（IL-6） in patients with nonalcoholic fatt...Objective：To evaluate the effect of Xuezhikang Capsule（血脂康胶囊） on the serum levels of inflammatory factors such as tumor necrosis factor-α（TNF-α） and interleukin-6（IL-6） in patients with nonalcoholic fatty liver disease（NAFLD） and hyperlipidemia,and to explore whether it has anti-inflammatory effect.Methods：A total of 84 patients were randomly assigned to two groups with stratified block randomization, the treatment group（42 cases） and the control group（42 cases）.They were treated with Xuezhikang Capsule and polyene phosphatidylcholine capsule for twenty-four weeks,respectively.The changes in serum TNF-αand IL-6 were measured by enzyme linked immunosorbent assay before treatment and at the 12th and 24th week. Results：Compared with those before treatment,the serum levels of TNF-αand IL-6 significantly decreased in both groups after treatment（P〈0.01）.There was no significant change between the two groups for the treatments at different time points（P〉0.05） and between the two groups for treatments at the same time points （P〉0.05）.Conclusion：Xuezhikang Capsule can inhibit the serum inflammatory factor in patients with NAFLD and hyperlipidemia.展开更多
目的:观察壳脂胶囊治疗非酒精性脂肪肝(NAFLD)的临床疗效及安全性。方法:选择符合标准的非酒精性脂肪肝门诊患者60例,随机分为治疗组(壳脂胶囊组30例)及对照组(血脂康组30例),分别予壳脂胶囊1.25 g tid和血脂康0.6 g bid,疗程24周。结果...目的:观察壳脂胶囊治疗非酒精性脂肪肝(NAFLD)的临床疗效及安全性。方法:选择符合标准的非酒精性脂肪肝门诊患者60例,随机分为治疗组(壳脂胶囊组30例)及对照组(血脂康组30例),分别予壳脂胶囊1.25 g tid和血脂康0.6 g bid,疗程24周。结果:两组在降低天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆固醇(TC)、甘油三酯(TG)、低密度胆固醇(LDL-C)、肌酐(CREAT)、尿素氮(BUN)、体质量指数(BMI),症状积分,B超影像学指标表现等方面均有显著疗效;其中血脂康组在降低TC、TG方面,优于壳脂胶囊组,差异有统计学意义(P<0.05);壳脂胶囊组在降低BMI、症状疗效、B超疗效等方面,优于血脂康组,差异有统计学意义(P<0.05)。结论:壳脂胶囊治疗NAFLD有一定效果;且无明显不良反应。展开更多
目的探讨血脂康在合并高血压患者中的冠心病二级预防效果。方法对一项随机、双盲、安慰剂对照试验中的2704例合并高血压、2166例不合并高血压的冠心病患者的干预结果进行分析,并对高血压患者按照脉压分组进行统计。结果冠心病合并高血...目的探讨血脂康在合并高血压患者中的冠心病二级预防效果。方法对一项随机、双盲、安慰剂对照试验中的2704例合并高血压、2166例不合并高血压的冠心病患者的干预结果进行分析,并对高血压患者按照脉压分组进行统计。结果冠心病合并高血压患者的冠心病事件的发生率和总死亡率明显高于不合并高血压的患者。在合并高血压患者中,高脉压组(脉压>50 mm Hg,1mm Hg=0.133 kPa)患者的死亡率和脑卒中发生率明显高于低脉压组(脉压≤50 mm Hg)患者。与对照组比较,冠心病事件和总死亡率在合并高血压患者中分别降低44.0%(P<0.0001)和35.8%(P=0.0012),在不合并高血压患者中分别降低47.4%(P<0.0001)和28.6%(P=0.0737)。在全部合并高血压的患者中,肿瘤死亡减少67.5%(P=0.0071)。在低脉压组患者中,肿瘤事件减少62.6%(P=0.0399)。没有发现治疗组临床不良反应或实验室安全指标的增加。结论对冠心病合并高血压的患者应积极进行调脂治疗,血脂康用于高血压患者的冠心病二级预防是安全有效的。展开更多
文摘Objective：To evaluate the effect of Xuezhikang Capsule（血脂康胶囊） on the serum levels of inflammatory factors such as tumor necrosis factor-α（TNF-α） and interleukin-6（IL-6） in patients with nonalcoholic fatty liver disease（NAFLD） and hyperlipidemia,and to explore whether it has anti-inflammatory effect.Methods：A total of 84 patients were randomly assigned to two groups with stratified block randomization, the treatment group（42 cases） and the control group（42 cases）.They were treated with Xuezhikang Capsule and polyene phosphatidylcholine capsule for twenty-four weeks,respectively.The changes in serum TNF-αand IL-6 were measured by enzyme linked immunosorbent assay before treatment and at the 12th and 24th week. Results：Compared with those before treatment,the serum levels of TNF-αand IL-6 significantly decreased in both groups after treatment（P〈0.01）.There was no significant change between the two groups for the treatments at different time points（P〉0.05） and between the two groups for treatments at the same time points （P〉0.05）.Conclusion：Xuezhikang Capsule can inhibit the serum inflammatory factor in patients with NAFLD and hyperlipidemia.
文摘目的:观察壳脂胶囊治疗非酒精性脂肪肝(NAFLD)的临床疗效及安全性。方法:选择符合标准的非酒精性脂肪肝门诊患者60例,随机分为治疗组(壳脂胶囊组30例)及对照组(血脂康组30例),分别予壳脂胶囊1.25 g tid和血脂康0.6 g bid,疗程24周。结果:两组在降低天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆固醇(TC)、甘油三酯(TG)、低密度胆固醇(LDL-C)、肌酐(CREAT)、尿素氮(BUN)、体质量指数(BMI),症状积分,B超影像学指标表现等方面均有显著疗效;其中血脂康组在降低TC、TG方面,优于壳脂胶囊组,差异有统计学意义(P<0.05);壳脂胶囊组在降低BMI、症状疗效、B超疗效等方面,优于血脂康组,差异有统计学意义(P<0.05)。结论:壳脂胶囊治疗NAFLD有一定效果;且无明显不良反应。
文摘目的探讨血脂康在合并高血压患者中的冠心病二级预防效果。方法对一项随机、双盲、安慰剂对照试验中的2704例合并高血压、2166例不合并高血压的冠心病患者的干预结果进行分析,并对高血压患者按照脉压分组进行统计。结果冠心病合并高血压患者的冠心病事件的发生率和总死亡率明显高于不合并高血压的患者。在合并高血压患者中,高脉压组(脉压>50 mm Hg,1mm Hg=0.133 kPa)患者的死亡率和脑卒中发生率明显高于低脉压组(脉压≤50 mm Hg)患者。与对照组比较,冠心病事件和总死亡率在合并高血压患者中分别降低44.0%(P<0.0001)和35.8%(P=0.0012),在不合并高血压患者中分别降低47.4%(P<0.0001)和28.6%(P=0.0737)。在全部合并高血压的患者中,肿瘤死亡减少67.5%(P=0.0071)。在低脉压组患者中,肿瘤事件减少62.6%(P=0.0399)。没有发现治疗组临床不良反应或实验室安全指标的增加。结论对冠心病合并高血压的患者应积极进行调脂治疗,血脂康用于高血压患者的冠心病二级预防是安全有效的。
